Evidence is mounting that 2 immunotherapies are better than 1 as first-line treatment of patients with advanced melanoma. A phase 3 clinical trial showed that nivolumab plus ipilimumab was superior to ipilimumab or nivolumab alone, and a phase 1 trial suggests that pembrolizumab can be safely and effectively used in combination with other drugs as first-line treatment in this setting. Both studies were presented at ASCO 2016.
Chicago, IL—Data continue to build for the application of immunotherapy for patients with metastatic melanoma. At ASCO 2013, several sessions were devoted to recent advances in melanoma, focusing on new ways to boost the activity of current therapies, introducing a new class of immunotherapy in development, and a new form of immunotherapy—an oncolytic vaccine.
Metastatic melanoma traditionally carries a dismal prognosis, and few patients live >1 year after the diagnosis. But the tide is turning, with the emergence of 2 novel treatments shown to prolong survival.
Positive Results with BRAF Inhibitor
Results 1 - 3 of 3